Bupropion

Generic Name: Bupropion

Brand Names: Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈ClNO

CAS Number: 34911-55-2

Unique Ingredient Identifier: 01ZG3TPX31

Background: Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...

Indication: Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)

Associated Therapies: Smoking, Cessation, Weight Loss

Clinical Trials

Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women

Phase 2

Completed

Conditions: Smoking
Nicotine Dependence

Interventions: Drug: Bupropion

First Posted Date: 2014-07-11

Last Posted Date: 2021-05-04

Lead Sponsor: Henry Kranzler

Target Recruit Count: 129

Registration Number: NCT02188459

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Christiana Care Health System, Newark, Delaware, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

The MATCH (Medication Aids for Tobacco Cessation and Health) Study

Not Applicable

Completed

Conditions: Nicotine Dependence
Tobacco Use Disorder

Interventions: Drug: Bupropion
Drug: Varenicline
Behavioral: Weekly Motivational Emails

First Posted Date: 2014-05-26

Last Posted Date: 2017-02-02

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 968

Registration Number: NCT02146911

Locations: 🇨🇦
Centre for Addiction and Mental Health, Nicotine Dependence Clinic, Toronto, Ontario, Canada

Effects of Bupropion in Depression

Not Applicable

Completed

Conditions: Depression

Interventions: Drug: Bupropion

First Posted Date: 2014-04-04

Last Posted Date: 2016-05-12

Lead Sponsor: University of Oxford

Target Recruit Count: 80

Registration Number: NCT02104128

Locations: 🇬🇧
University of Oxford, Oxford, Oxfordshire, United Kingdom

PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Bupropion

First Posted Date: 2014-01-20

Last Posted Date: 2016-08-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT02039960

Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD

Not Applicable

Completed

Conditions: PTSD
Smoking

Interventions: Drug: Bupropion
Drug: nicotine replacement therapy
Other: Smoking cessation counseling
Behavioral: mobile contingency management
Other: Stay Quit Coach

First Posted Date: 2013-11-21

Last Posted Date: 2015-09-17

Lead Sponsor: Duke University

Target Recruit Count: 15

Registration Number: NCT01990079

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Smoking Cessation for People Living With HIV/AIDS

Not Applicable

Conditions: HIV
AIDS
Nicotine Dependence

Interventions: Drug: Bupropion
Behavioral: Brief Counseling
Behavioral: Monitored support to quit smoking
Behavioral: No additional treatment
Behavioral: High-magnitude prize contingency management
Behavioral: Prize contingency management for abstinence
Behavioral: Low intensity prize contingency management

First Posted Date: 2013-10-18

Last Posted Date: 2021-07-02

Lead Sponsor: Wayne State University

Target Recruit Count: 165

Registration Number: NCT01965405

Locations: 🇺🇸
Tolan Park Medical Building, Detroit, Michigan, United States

A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults

Phase 4

Withdrawn

Conditions: Depressive Disorder Not Otherwise Specified (NOS)
Major Depressive Disorder
Dysthymic Disorder

Interventions: Behavioral: Problem Solving Therapy
Drug: Aripiprazole
Drug: Bupropion

First Posted Date: 2013-09-13

Last Posted Date: 2019-04-18

Lead Sponsor: New York State Psychiatric Institute

Registration Number: NCT01942187

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Apathy Cure Through Bupropion in Huntington's Disease

Phase 2

Completed

Conditions: Huntington's Disease
Apathy

Interventions: Drug: Bupropion
Drug: Placebo

First Posted Date: 2013-08-02

Last Posted Date: 2014-09-09

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 40

Registration Number: NCT01914965

Locations: 🇩🇪
Neurologische Klinik der Ruhr-Universität Bochum, Bochum, Germany
🇩🇪
Universitätsklinikum Ulm, Klinik für Neurologie, Ulm, Germany

CPT and Smoking Cessation

Phase 2

Completed

Conditions: Stress Disorders, Post-Traumatic
Smoking

Interventions: Behavioral: Cognitive Processing Therapy (CPT)
Drug: Bupropion
Drug: nicotine replacement therapy (NRT)
Behavioral: Integrated Care for Smoking Cessation (ICSC)
Behavioral: smokefreeVET

First Posted Date: 2013-07-17

Last Posted Date: 2018-09-11

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 69

Registration Number: NCT01901848

Locations: 🇺🇸
Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States

Interpersonal Psychotherapy for Treatment Resistant Depression

First Posted Date: 2013-07-11

Last Posted Date: 2013-07-11

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 74

Registration Number: NCT01896349

Locations: 🇧🇷
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy